论文部分内容阅读
Ge-132是有机锗类化合物中最早用作抗肿瘤的药物,六十年代由日本浅井一彦首次报道。七十年代中期,人们通过对Ge-132晶体结构的测定,发现了此化合物具独特的网状结构;且经生理活性研究,发现它是一种新型的抗癌药。 Ge-132是一种低毒的有效抗癌药物,又是一种较好的缺氧细胞增敏剂。动物实验表明,Ge-132对艾氏腹水癌的抑制率为25.91％。其毒性小,小鼠口服>10g/Kg时才产生急性毒性。在慢性毒性试验中,大鼠每日口服30～3000mg/Kg,长达六个月,亦未出现异常症状。各种功能试验、血象、器官重量等均与正常鼠一致,且均存活。临床研究表明,Ge-132对胃癌、肺癌、子宫癌、
Ge-132 is one of the earliest organic anti-tumor drugs used in organo-germanium compounds. It was firstly reported by Asai Asai in the 1960s. The mid-seventies, people through the determination of Ge-132 crystal structure, found that this compound has a unique network structure; and the physiological activity of the study and found that it is a new type of anticancer drug. Ge-132 is a low toxicity and effective anti-cancer drugs, but also a better hypoxia cell sensitizer. Animal experiments show that, Ge-132 on Ehrlich ascites carcinoma inhibition rate was 25.91%. Its toxicity, mice oral> 10g / Kg only when acute toxicity. In the chronic toxicity test, rats were orally administered 30 to 3000 mg / kg daily for up to six months without any abnormal symptoms. A variety of functional tests, blood, organ weight, etc. are consistent with normal mice, and all survived. Clinical studies have shown that Ge-132 on gastric cancer, lung cancer, uterine cancer,